All In Biotech

Drug Trial Radar · NCT01987297

Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL

Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study

Last checked: Nov 20, 2026Latest source record: Aug 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 738 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

738

Planned (sponsor's estimate)

Start

Jun 2012

Primary completion

Dec 31, 2020

Study completion Dec 31, 2020

Sponsor

Lead sponsor
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tang-Du Hospital; Peking University People's Hospital; First Affiliated Hospital of Zhejiang University; Tongji Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; First Hospital of China Medical University; Southwest Hospital, China; West China Hospital; Ningbo No. 1 Hospital; Qilu Hospital of Shandong University; Shandong Provincial Hospital; Union hospital of Fujian Medical University; First Affiliated Hospital of Guangxi Medical University; Guangdong Provincial People's Hospital; First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital of Soochow University; The First Affiliated Hospital with Nanjing Medical University; The Second Affiliated Hospital of Dalian Medical University; Nanfang Hospital, Southern Medical University; The First Affiliated Hospital of Anhui Medical University; Institute of Hematology & Blood Diseases Hospital, China
First posted
Nov 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this prospective randomized study for patients with newly diagnosed acute promyelocytic leukemia, patients will be randomized (1:1) into two groups which receive retinoic acid and arsenic trioxide based treatment versus retinoic acid and chemotherapy based regimen.

Conditions

  • Acute Promyelocytic Leukemia

Interventions

  • ATRA+ArsenicDrug

    ATRA: 25mg/m2 daily;Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course. Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course. Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses. MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients.

  • ATRA+ChemoDrug

    ATRA: 25mg/m2 daily;Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course. Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course. Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses. Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course. MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free survival (DFS)Time frame: 3 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Hematology

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.